A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor

Vaccine
V LohrU Reichl

Abstract

An adherently growing MDCK cell line was adapted in a two-step process in a fully defined medium and in suspension. The resulting MDCK.SUS2 cells were subsequently evaluated for their potential as host cells for influenza vaccine production in two lab-scale bioreactors (wave and stirred-tank). Cell concentrations up to 2.3 x 10(6)cells/mL were obtained after 96 h, which is slightly higher than cell concentrations obtained with adherent MDCK cells cultivated on microcarriers (2g/L). Infections with influenza A/PR/8/34 and B/Malaysia resulted in high virus titers (2.90 and 2.75 log HA units/100 microL, respectively). The monitoring of extracellular metabolites, including amino acids, revealed a change in some of the metabolite consumption or release profiles, which indicates changes in metabolism during the adaptation process. Overall, the MDCK.SUS2 cell line represents a new cell substrate for a robust influenza vaccine production in a fully defined process.

References

Jan 1, 1992·Pharmacology & Therapeutics·U Bjare
Jul 6, 2004·Journal of Virological Methods·R YouilD DiStefano
Jun 19, 2008·Biologicals : Journal of the International Association of Biological Standardization·Bernd KalbfussUdo Reichl
Dec 1, 2000·Journal of Veterinary Cardiology : the Official Journal of the European Society of Veterinary Cardiology·J Häggström
Jun 3, 2009·Expert Review of Vaccines·Alexander Doroshenko, Scott A Halperin
Jun 30, 2009·Vaccine·Jonathan LiuGeorge Kemble
Dec 1, 2009·Expert Review of Vaccines·Yvonne Genzel, Udo Reichl

❮ Previous
Next ❯

Citations

Jul 24, 2012·Applied Microbiology and Biotechnology·Yvonne GenzelUdo Reichl
Jul 19, 2015·Vaccine·Françoise AubritKlaus Schwamborn
Aug 1, 2012·Biotechnology Progress·Petiot Emma, Amine Kamen
May 23, 2015·Applied Microbiology and Biotechnology·R CastroA S Coroadinha
Jan 10, 2012·Virology·Andrea Timm, John Yin
Apr 16, 2015·Human Vaccines & Immunotherapeutics·Nagendra R Hegde
Jul 17, 2015·Expert Review of Vaccines·Lilí Esmeralda Gallo-RamírezUdo Reichl
Jul 8, 2017·Archives of Virology·Honglin WangGuicai Song
Apr 20, 2018·Human Vaccines & Immunotherapeutics·Alberto Pérez Rubio, Jose María Eiros
Apr 4, 2020·Journal of Biomedical Science·Tsai-Teng TzengAlan Yung-Chih Hu
Jul 18, 2017·Engineering in Life Sciences·Frank HämmerlingJürgen Hubbuch
Sep 29, 2011·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·John Steel
Aug 29, 2020·International Journal of Molecular Sciences·Ana Filipa RodriguesAna Sofia Coroadinha
Jul 17, 2018·Journal of Chemical Technology and Biotechnology·Sofia B CarvalhoManuel Jt Carrondo
Jul 6, 2021·Biotechnology and Bioengineering·Thomas BissingerUdo Reichl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.